$IDRA $3.37
called 8/21/13 $1.69


WebSite

Nasdaq
Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor
Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic
MYD88 L265P Mutation
4/7/2014 4:05:00 PM - Business Wire

Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings
and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
4/4/2014 8:00:00 AM - PR Newswire

Idera Soars on Phase II Drug Data - Analyst Blog
3/31/2014 5:06:01 PM - Zacks.com

Idera Pharma Reports Positive Top-line Data From Phase 2 Trial Of IMO-8400
3/28/2014 7:30:00 AM - RTT News

Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400
3/28/2014 7:15:00 AM - Business Wire

10-K
3/13/14
O/S shares 82,360,165

Last trades

StockWatch


% Opinion